#United States #Tampa #Cancer Immunotherapy #TuHURA Biosciences #HURA

TuHURA Biosciences Reports Strong 2025 Results

TuHURA Biosciences, Inc., traded under NASDAQ as HURA, has recently shared its financial results for the fourth quarter and the full year ending December 31, 2025. The company, a prominent player in Phase 3 immuno-oncology, is dedicated to developing innovative therapies aimed at overcoming the challenges of cancer immunotherapy.

Overview of Financial Performance

In their report, TuHURA highlighted a robust year of operational execution. Their total cash and cash equivalents stood at $3.6 million as of December 31, 2025. Additionally, they received $7.5 million in the first quarter of 2026, resulting from a registered direct offering. The firm reported research and development expenses of $20.5 million, which marked an increase from $13.3 million in the previous year, underscoring their commitment to research and clinical development. This includes the financial impact of their acquisition of Kineta, which was finalized in mid-2025 for $10.5 million.

General and administrative expenses also saw a rise, totaling $7.6 million compared to $3.9 million the previous year. Despite these escalated expenditures, TuHURA managed to secure $19.9 million in financing activities, albeit with net cash outflows from operations reaching $27.7 million, indicating significant investment in growth and development in line with their strategic objectives.

Enhancements to the Clinical Pipeline

Dr. James Bianco, President and CEO of TuHURA, expressed optimism regarding the company's trajectory, citing the strategic enhancement of their clinical and drug development capabilities. Recently, Craig Tendler, M.D., joined the team to provide essential oversight on the clinical development strategies, including supervising the company's promising assets such as the VISTA inhibiting antibody, TBS-2025.

The company has also initiated a randomized Phase 3 Accelerated Approval Trial for IFx-2.0, designed for first-line treatment in patients with advanced Merkel Cell Carcinoma (MCC) in conjunction with Keytruda® (pembrolizumab). The primary goal of this trial is to measure the Overall Response Rate (ORR), which qualifies for the expedited approval pathway by the FDA.

Research and Development Highlights

TuHURA continues to advance its clinical programs, with significant strides made in their ADC (antibody-drug conjugate) candidates and the immune modulating programs. The company anticipates sharing substantial data at upcoming scientific conferences, furthering their commitment to innovative cancer treatments.

Moreover, their first-in-class ADC program aims to establish proof-of-concept within the ongoing year, which underscores their dedication toward advancing cancer treatment options. They also revealed that results from the Phase 1b/2 study of IFx-2.0 are expected in the latter half of 2026, along with an upcoming meeting in June of that year with the FDA to strategize on the development plan for TBS-2025.

Acknowledging Support from Shareholders

Throughout these developments, Dr. Bianco acknowledged the consistent support from shareholders. He reiterated the potential impact of their studies and the transformative opportunities they present for patients battling cancer. As they navigate the complexities of cancer research, TuHURA is focused on ensuring that its innovative therapies reach those who need them most.

Future Milestones

Moving forward, the company is setting several ambitious milestones, including:

• - Anticipation of Orphan Drug Designation for IFx-2.0 in MCC by mid-2026.
• - Initial data from the Phase 1b/2 study by late 2026.
• - Topline results from the Phase 3 accelerated trial by late 2027.

In summary, 2025 was a pivotal year for TuHURA, and with the addition of experienced professionals and a strong financial backing, the future seems promising for the advancement of their immunotherapy pipeline. For ongoing updates and developments, interested parties are encouraged to visit their official website and engage with them via social media platforms including Facebook, LinkedIn, and X.